research Discovering Hair Loss Treatments That Increase The Wnt/Beta-Catenin Signaling Pathway By High-Throughput Screening
Aminoacridine and Abemaciclib, especially combined with Minoxidil, show promise for treating hair loss.
Search
forLearn
0 / 0 results — no results
Research
5 / 12 results
research Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm
CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
research Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report
Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.
research Fatigue, Alopecia, and Stomatitis Among Patients With Breast Cancer Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Systematic Review and Meta-Analysis
Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
research Safety and Patient-Reported Outcomes in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated With CDK4/6 Inhibitors in China: A Cross-Sectional Study
Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
Community Join
0 / 0 results — no results